The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome
Open accessAbstract
Purpose: Preliminary studies suggested that telotristat ethyl, a tryptophan hydroxylase inhibitor, reduces bowel movement (BM) frequency in patients with carcinoid syndrome. This placebo-controlled phase III study evaluated telotristat ethyl in this setting. Patients and Methods: Patients (N = 135) experiencing four or more BMs per day despite stable-dose somatostatin analog therapy received (1:1:1) placebo, telotristat ethyl 250 mg, or telotristat ethyl 500 mg three times per day orally during a 12-week double-blind treatment period. The primary end point was change from baseline in BM frequency. In an open-label extension, 115 patients subsequently received telotristat ethyl 500 mg. Results: Estimated differences in BM frequency per day versus placebo averaged over 12 weeks were –0.81 for telotristat ethyl 250 mg ( P < .001) and ‒0.69 for telotristat ethyl 500 mg ( P < .001). At week 12, mean BM frequency reductions per day for placebo, telotristat ethyl 250 mg, and telotristat ethyl 500 mg were –0.9, –1.7, and –2.1, respectively. Responses, predefined as a BM frequency reduction ≥ 30% from baseline for ≥ 50% of the double-blind treatment period, were observed in 20%, 44%, and 42% of patients given placebo, telotristat ethyl 250 mg, and telotristat ethyl 500 mg, respectively. Both telotristat ethyl dosages significantly reduced mean urinary 5-hydroxyindole acetic acid versus placebo at week 12 ( P < .001). Mild nausea and asymptomatic increases in gamma-glutamyl transferase were observed in some patients receiving telotristat ethyl. Follow-up of patients during the open-label extension revealed no new safety signals and suggested sustained BM responses to treatment. Conclusion: Among patients with carcinoid syndrome not adequately controlled by somatostatin analogs, treatment with telotristat ethyl was generally safe and well tolerated and resulted in significant reductions in BM frequency and urinary 5-hydroxyindole acetic acid.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Case-finding instruments for depression: Two questions are as good as many
Whooley, M. A., Avins, A. L., Miranda, J., & Browner, W. S. (1997) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.1997.00076.x · Cited by 1,826
Boudreaux, J. P., Klimstra, D. S., Hassan, M. M., Woltering, E. A., Jensen, R. T., Goldsmith, S. J., Nutting, C., Bushnell, D. L., Caplin, M. E., & Yao, J. C. (2010) · Pancreas · doi:10.1097/mpa.0b013e3181ebb2a5 · Cited by 539
Self-citationRubin, J., Ajani, J., Schirmer, W., Venook, A. P., Bukowski, R., Pommier, R., Saltz, L., Dandona, P., & Anthony, L. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.600 · Cited by 389
Self-citationKulke, M. H., Siu, L. L., Tepper, J. E., Fisher, G., Jaffe, D., Haller, D. G., Ellis, L. M., Benedetti, J. K., Bergsland, E. K., Hobday, T. J., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.2056 · Cited by 304
Self-citationSerotonin receptors and heart valve disease—It was meant 2B
Hutcheson, J. D., Setola, V., Roth, B. L., & Merryman, W. D. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.03.008 · Cited by 252
Yao, J. C., Pavel, M., Phan, A. T., Kulke, M. H., Hoosen, S., St. Peter, J., Cherfi, A., & Öberg, K. E. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0666 · Cited by 225
Self-citationWolin, E., Jarzab, B., Eriksson, B., Walter, T., Toumpanakis, C., Morse, M. A., Tomassetti, P., Weber, M. M., Fogelman, D., Ramage, J., et al. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s84177 · Cited by 210
Self-citationRuszniewski, P., Ducreux, M., Chayvialle, J. A., Blumberg, J., Cloarec, D., Michel, H., Raymond, J. M., Dupas, J. L., Gouerou, H., Jian, R., et al. (1996) · Gut · doi:10.1136/gut.39.2.279 · Cited by 206
Engelman, K., Lovenberg, W., & Sjoerdsma, A. (1967) · New England Journal of Medicine · doi:10.1056/nejm196711232772101 · Cited by 197
Placebo effect in double-blind clinical trials: a review of interactions with medications
Kleijnen, J., de Craen, A. J. M., van Everdingen, J., & Krol, L. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90699-8 · Cited by 189
Cited by
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac244 · Cited by 3,076
Pavel, M., Öberg, K., Falconi, M., Krenning, E. P., Sundin, A., Perren, A., & Berruti, A. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.304 · Cited by 1,179
Self-citationGastroenteropancreatic Neuroendocrine Tumors
Cives, M., & Strosberg, J. R. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21493 · Cited by 586
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeac106 · Cited by 507
Strosberg, J. R., Halfdanarson, T. R., Bellizzi, A. M., Chan, J. A., Dillon, J. S., Heaney, A. P., Kunz, P. L., O’Dorisio, T. M., Salem, R., Segelov, E., et al. (2017) · Pancreas · doi:10.1097/mpa.0000000000000850 · Cited by 373
Self-citation
Metadata
- Authors
- Kulke, M. H., Hörsch, D., Caplin, M. E., Anthony, L. B., Bergsland, E., Öberg, K., Welin, S., Warner, R. R. P., Lombard-Bohas, C., Kunz, P. L., Grande, E., Valle, J. W., Fleming, D., Lapuerta, P., Banks, P., Jackson, S., Zambrowicz, B., Sands, A. T., & Pavel, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2017-01-01
- Volume
- 35
- Issue
- 1
- Pages
- 14-23
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2547287898
- Cited by
- 303
- References
- 21
- FWCI
- 30.79
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome. https://app.cochat.ai/papers/10.1200/jco.2016.69.2780
- The paper
- Kulke, M. H., Hörsch, D., Caplin, M. E., Anthony, L. B., Bergsland, E., Öberg, K., Welin, S., Warner, R. R. P., Lombard-Bohas, C., Kunz, P. L., Grande, E., Valle, J. W., Fleming, D., Lapuerta, P., Banks, P., Jackson, S., Zambrowicz, B., Sands, A. T., & Pavel, M. (2017). Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2016.69.2780
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.